165 related articles for article (PubMed ID: 37152028)
1. Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.
Wu X; Wang Q; Xu X
Front Oncol; 2023; 13():1156329. PubMed ID: 37152028
[TBL] [Abstract][Full Text] [Related]
2.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
4. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.
Argani P; Lian DWQ; Agaimy A; Metzler M; Wobker SE; Matoso A; Epstein JI; Sung YS; Zhang L; Antonescu CR
Am J Surg Pathol; 2021 May; 45(5):653-661. PubMed ID: 33399341
[TBL] [Abstract][Full Text] [Related]
6. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
7.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
8. A Rare
Yang Y; Qin SK; Zhu J; Wang R; Li YM; Xie ZY; Wu Q
Mayo Clin Proc Innov Qual Outcomes; 2017 Jul; 1(1):111-116. PubMed ID: 30225407
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
Mian I; Abdullaev Z; Morrow B; Kaplan RN; Gao S; Miettinen M; Schrump DS; Zgonc V; Wei JS; Khan J; Pack S; Hassan R
J Thorac Oncol; 2020 Mar; 15(3):457-461. PubMed ID: 31783178
[TBL] [Abstract][Full Text] [Related]
10. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.
Agaimy A; Baněčková M; Ihrler S; Mueller SK; Franchi A; Hartmann A; Stoehr R; Skálová A
Am J Surg Pathol; 2021 Sep; 45(9):1166-1178. PubMed ID: 33871952
[TBL] [Abstract][Full Text] [Related]
11. Ovarian metastases from
Li H; Chen Y; Wang Y; Zhou L; Tian Z; Liu M; Li Y; Xu H; Wu W; Gong Z
Transl Cancer Res; 2022 Sep; 11(9):3391-3399. PubMed ID: 36237252
[TBL] [Abstract][Full Text] [Related]
12. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
[TBL] [Abstract][Full Text] [Related]
13. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.
Zhu L; Ma S; Xia B
Front Oncol; 2022; 12():1009076. PubMed ID: 36439495
[TBL] [Abstract][Full Text] [Related]
14. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
15. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract][Full Text] [Related]
16. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells.
Murumägi A; Ungureanu D; Arjama M; Bützow R; Lohi J; Sariola H; Kanerva J; Koskenvuo M; Kallioniemi O
Transl Oncol; 2021 Apr; 14(4):101027. PubMed ID: 33530027
[TBL] [Abstract][Full Text] [Related]
17. Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer.
Lee KA; Lee JS; Min JK; Kim HJ; Kim WS; Lee KY
Tuberc Respir Dis (Seoul); 2014 Dec; 77(6):258-61. PubMed ID: 25580142
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.
Li X; Zheng J; Li X; Chen Y; Liu K; Li F; Lu Z
Front Oncol; 2023; 13():1252221. PubMed ID: 37869075
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.
Loharamtaweethong K; Puripat N; Aoonjai N; Sutepvarnon A; Bandidwattanawong C
Histopathology; 2016 Mar; 68(4):603-7. PubMed ID: 26179668
[TBL] [Abstract][Full Text] [Related]
20. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
